Aeluma, Inc. disclosed that its President, CEO, and Chairman, Dr. Jonathan Klamkin, has terminated his Rule 10b5-1 trading arrangement. The plan, originally adopted in May 2026, provided for the potential sale of up to 300,000 shares of the company's common stock.
Key Details
- Action Taken: Dr. Klamkin terminated the 10b5-1 trading arrangement on October 21, 2026.
- Original Plan: The arrangement was adopted on May 23, 2026, and provided for the sale of up to 300,000 shares.
- Executive: The plan was held by Dr. Jonathan Klamkin, who serves as the company's President, CEO, and Chairman.